Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients
Sponsor: Seoul National University Hospital
Summary
The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.
Official title: Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-10
Completion Date
2028-10
Last Updated
2026-10-26
Healthy Volunteers
No
Interventions
RSVPreF3 vaccination
One dose of RSVPreF3 (Arexvy®) vaccine
Locations (1)
Seoul National University Hospital
Seoul, Jongno-Gu, South Korea